Sunday, January 26, 2020

FDA Keeps Brand-Name Drugs on a Fast Path to Market ― Despite Manufacturing Concerns | The Fix

FDA Keeps Brand-Name Drugs on a Fast Path to Market ― Despite Manufacturing Concerns | The Fix: Even some of the newest, most expensive brand-name medicines have been plagued by quality and safety concerns during production, a Kaiser Health News analysis shows.

No comments:

Post a Comment